Given the efficacy of these drugs shown by other groups, we did not propose a control group and we started treatment in those subjects in whom it was considered that GLP-1 RAs could provide special benefits, such as obese diabetic subjects
Some minor side effects, such as nausea or injection site reactions, may occur but typically resolve on their own
Preliminary results on 30 patients showed a 42% improvement in the ECCA scarring score after three sessions of microneedling combined with GHK-Cu + PRP, versus 28% with PRP alone
However, as clinicians celebrate these advances, a Read More Why Early Combination Therapy Is Gaining Momentum in Young-Onset Type 2 Diabetes May 19, 2026 Articles, Blood Glucose Control, Devices, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Metformin Therapy Center, SGLT-2 Therapy Center, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,711 views Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults
doi: 10.7759/cureus.26995
et al.(2023) "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial" The Lancet, 402(10403) This article was reviewed by and approved by Alice Fletcher, Bariatric Dietitian, on 28 February 2025